A Score Based on NfL and Glial Markers May Differentiate Between Relapsing–Remitting and Progressive MS Course

Background: The diagnostic use of biomarkers in body fluids of multiple sclerosis (MS) patients allows the monitoring of different pathophysiological aspects of the disease. We previously reported elevated cerebrospinal fluid (CSF) and serum levels of glial fibrillary acidic protein (GFAP) but not n...

Descripción completa

Detalles Bibliográficos
Autores principales: Huss, André, Otto, Markus, Senel, Makbule, Ludolph, Albert C., Abdelhak, Ahmed, Tumani, Hayrettin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378743/
https://www.ncbi.nlm.nih.gov/pubmed/32765393
http://dx.doi.org/10.3389/fneur.2020.00608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378743/
https://www.ncbi.nlm.nih.gov/pubmed/32765393
http://dx.doi.org/10.3389/fneur.2020.00608

Ejemplares similares